Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Asset Writedowns and Impairment (2022 - 2025)

Neuronetics (STIM) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $205000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 71.09% to $205000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$939000.0, a 147.71% decrease, with the full-year FY2024 number at $626000.0, up 60.51% from a year prior.
  • Asset Writedowns and Impairment was $205000.0 for Q3 2025 at Neuronetics, up from $172000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.9 million in Q3 2023 to a low of -$1.3 million in Q4 2024.
  • A 4-year average of $223000.0 and a median of $121500.0 in 2024 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 295.81% in 2024; the steepest drop was 6390.48% in 2024.
  • Neuronetics' Asset Writedowns and Impairment stood at $13000.0 in 2022, then surged by 61.54% to $21000.0 in 2023, then plummeted by 6390.48% to -$1.3 million in 2024, then soared by 115.52% to $205000.0 in 2025.
  • Per Business Quant, the three most recent readings for STIM's Asset Writedowns and Impairment are $205000.0 (Q3 2025), $172000.0 (Q2 2025), and $5000.0 (Q1 2025).